Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$51.21
$1.32(2.62%)
At close: 4:00 PM EDT
$51.21
$1.32(2.62%)
Day’s Range― - ―
52-Week Range$42.62 - $71.07
Previous Close$51.72
Volume439.54K
Average Volume (3M)612.86K
Market Cap
$2.34B
Enterprise Value$4.23B
Total Cash (Recent Filing)$89.13M
Total Debt (Recent Filing)$2.06B
Price to Earnings (P/E)13.3
Beta0.39
Next Earnings
Nov 05, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend Yield1.25%
Share Statistics
EPS (TTM)3.59
Shares Outstanding47,374,523
10 Day Avg. Volume527,157
30 Day Avg. Volume612,862
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.65
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue3.83
Enterprise Value/Gross Profit7.19
Enterprise Value/Ebitda13.52
Forecast
1Y Price Target
$72.00Price Target Upside40.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.58
Revenue Forecast (FY)$1.30B
Bulls Say, Bears Say
Bulls Say
Acquisition-Led GrowthBreathe Right and LaCorium materially expand Prestige’s revenue base while adding exposure to respiratory and therapeutic skincare categories. Their expected accretion and integration through existing systems could improve scale, distribution leverage, and long-term earnings growth.
Strong Free Cash FlowRobust free cash flow provides internal funding for debt reduction, marketing, acquisitions, and operating investment. High cash conversion strengthens financial flexibility and supports the company’s ability to integrate brands while maintaining its broader growth strategy.
Profitable Diversified PortfolioPrestige’s broad branded OTC portfolio addresses recurring consumer health needs across multiple categories and channels. This diversification can reduce dependence on any single product, support retailer relevance, and provide a platform for marketing and distribution efficiencies.
Bears Say
Meaningful Leverage CostsMeaningful leverage and higher interest expense can absorb a substantial portion of operating cash flow, limiting flexibility for further acquisitions, marketing, or shareholder returns. Debt reduction and successful integration remain important to preserving financial resilience.
Modest Organic GrowthAcquisitions are carrying much of the near-term reported growth outlook, while underlying organic expansion remains modest. Limited core growth may constrain operating leverage and make future performance more dependent on successful brand investment and acquisition execution.
Supply And Margin PressureMulti-quarter supply variability and weaker gross margin can pressure product availability, revenue realization, and profitability. Although Clear Eyes is under 3% of sales, continued execution issues alongside transportation costs could weigh on margins during the integration period.
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $71.07 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.34B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Aug 06, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.894 by $0.086.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of 1.25%. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.07.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,374,523 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $0.98 in its last earnings report, beating expectations of $0.894. Following the earnings report the stock price went up 2.737%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.00 (40.60% Upside)
$72.00 (40.60% Upside)
Blogger Sentiment
Neutral
PBH Sentiment 60%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.93%
12-Months-Change
Fundamentals
Return on Equity
9.22%
Trailing 12-Months
Asset Growth
33.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBH Company Deck
PBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.View all PBH earnings summariesPBH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$72.00
▲(40.60% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
SCYNEXIS
―
Cosmos Holdings
―
Biofrontera
―
Nasus Pharma Ltd.
―
Clinuvel Pharmaceuticals Limited Sponsored ADR
―
Ownership Overview
1.38% Insiders
46.33% Mutual Funds
1.14% Other Institutional Investors
18.58% Public Companies and
Individual Investors









